Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy
ConclusionsPre-treatment serum TSH and ATAbs levels may help to identify patients at high risk for primary thyroid dysfunction. Our study suggests guidance for an appropriate timely screening and for a tailored management of thyroid dysfunctions in patients treated with ICIs.
Source: Journal of Endocrinological Investigation - Category: Endocrinology Source Type: research
More News: Cancer | Cancer & Oncology | Endocrinology | Immunotherapy | Study | Thyroid | Thyroid Cancer | Ultrasound